

Harold W De Valk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6494127/publications.pdf>

Version: 2024-02-01

32
papers

552
citations

687363

13
h-index

642732

23
g-index

33
all docs

33
docs citations

33
times ranked

790
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1894-1902.	4.4	77
2	Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3842-3853.	3.6	76
3	Insulin during pregnancy, labour and delivery. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 65-76.	2.8	48
4	A core outcome set for studies of gestational diabetes mellitus prevention and treatment. <i>Diabetologia</i> , 2020, 63, 1120-1127.	6.3	41
5	Pregnancy Outcome in Type 2 Diabetes Mellitus: A Retrospective Analysis from the Netherlands. <i>Review of Diabetic Studies</i> , 2006, 3, 134-134.	1.3	41
6	A core outcome set for studies evaluating the effectiveness of prepregnancy care for women with pregestational diabetes. <i>Diabetologia</i> , 2017, 60, 1190-1196.	6.3	36
7	High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000935.	2.8	36
8	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1424-1430.	8.6	31
9	High Diabetes Distress Among Ethnic Minorities Is Not Explained by Metabolic, Cardiovascular, or Lifestyle Factors: Findings From the Dutch Diabetes Pearl Cohort. <i>Diabetes Care</i> , 2018, 41, 1854-1861.	8.6	23
10	Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey. <i>Diabetologia</i> , 2019, 62, 2007-2016.	6.3	19
11	Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5977-5990.	3.6	19
12	Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. <i>Diabetes Care</i> , 2021, 44, 2069-2077.	8.6	14
13	Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2022, 100, 77-82.	2.2	14
14	Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 831-840.	3.7	10
15	DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. <i>Review of Diabetic Studies</i> , 2007, 4, 126-133.	1.3	9
16	Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109827.	2.8	8
17	Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 758-766.	4.4	7
18	Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients. <i>PLoS ONE</i> , 2015, 10, e0145597.	2.5	7

#	ARTICLE	IF	CITATIONS
19	SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e029808.	1.9	6
20	Cystic Fibrosis-Related Diabetes in Adults: Where Can We Go From Here?. <i>Review of Diabetic Studies</i> , 2007, 4, 6-6.	1.3	6
21	Needle Technology for Insulin Administration: A Century of Innovation. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 449-457.	2.2	6
22	Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107880.	2.8	5
23	DPARD: rationale, design and initial results from the Dutch national diabetes registry. <i>BMC Endocrine Disorders</i> , 2021, 21, 122.	2.2	5
24	Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 320-328.	4.4	3
25	Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 2159-2167.	2.5	2
26	Characteristics of pregnant women with diabetes using injectable glucose-lowering drugs in the EVOLVE study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 7992-8000.	1.5	2
27	Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008. <i>Review of Diabetic Studies</i> , 2008, 5, 184-188.	1.3	1
28	PS9 - 11. The importance of cardiovascular management in patients with cystic fibrosis after lung transplantation. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013, 11, 184-185.	0.0	0
29	PS9 - 13. Real-time continuous glucose monitoring during pregnancy on glycaemic control and maternal and fetal outcomes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013, 11, 192-192.	0.0	0
30	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 281-282.	1.3	0
31	Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2016;39:1424-1430. <i>Diabetes Care</i> , 2016, 39, e190-e191.	8.6	0
32	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 181.	6.8	0